Session Type: Concurrent Session
Date: Sunday, June 3, 2018
Session Time: 2:30pm-4:00pm
Presentation Time: 2:42pm-2:54pm
Location: Room 6B
ABO blood type-incompatible (ABOi) liver transplantation is one of the strategies employed to overcome the shortage of donor. By using the Rituximab and plasm exchange, it is successful to prevent the antibody mediated rejection which the preexist serum anti-A or anti-B antibodies is against the donor's blood group A or B antigens on graft. However, the outcome of long-term B cell immunity against donor blood group antigens in recipients who undergo ABOi living-donor liver transplantation (LDLT) is unknown.
There were 36 blood type O recipients who transplanted liver from 22 blood type A and 14 blood type B donors. We ex-vivo stimulated these ABOi LDLT recipients' B cells enriched from peripheral blood mononuclear cells (PBMC) by A, B, or O blood type red blood cell (RBC) to investigate the B cell phenotype, activity, and antibody production. The B cells from healthy O blood type volunteers served as control.
Donor-specific antibody titers in serum remained low (≤1:32) in all recipients. However, antibodies against non-donor blood group antigens were continuously higher (> 1:128) in recipients with blood type O. After stimulated by non-donor's blood type RBC, the B cells from O blood type recipients showed more active phenotype (CD45R+ or CD86+), but not when stimulated by donor's blood type RBC. The B cell s from O blood type recipients stimulated by non-donor's blood type RBC showed more proliferative activity on eFluor670 assay, but less proliferation when stimulated by donor's blood type RBC. Antibody production in cell culture supernatant investigated by flowcytometry against donor blood group antigens by cells from ABOi LDLT patients was lower than in the control groups.
These findings suggest diminished donor-specific B cell immune activity in the
setting of adult ABOi LDLT.
CITATION INFORMATION: Wu T-.J., Wang Y-.C., Cheng C-.H., Wu T-.H., Lee C-.F., Chou H., Chan K-.M., Lee W-.C. Donor-Specific B-Cell Tolerance after Successful ABO Blood Type Incompatible (ABOi) Living Donor Liver Transplantation (LDLT) Am J Transplant. 2017;17 (suppl 3).
To cite this abstract in AMA style:Wu T-J, Wang Y-C, Cheng C-H, Wu T-H, Lee C-F, Chou H, Chan K-M, Lee W-C. Donor-Specific B-Cell Tolerance after Successful ABO Blood Type Incompatible (ABOi) Living Donor Liver Transplantation (LDLT) [abstract]. https://atcmeetingabstracts.com/abstract/donor-specific-b-cell-tolerance-after-successful-abo-blood-type-incompatible-aboi-living-donor-liver-transplantation-ldlt/. Accessed September 25, 2023.
« Back to 2018 American Transplant Congress